[1]阎 丽,宋 迎.甲状腺激素与不同阶段2型糖尿病肾病的相关性研究[J].医学信息,2022,35(19):155-158.[doi:10.3969/j.issn.1006-1959.2022.19.045]
 YAN Li,SONG Ying.Study on the Correlation Between Thyroid Hormone and Different Stages of Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2022,35(19):155-158.[doi:10.3969/j.issn.1006-1959.2022.19.045]
点击复制

甲状腺激素与不同阶段2型糖尿病肾病的相关性研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年19期
页码:
155-158
栏目:
综述
出版日期:
2022-10-01

文章信息/Info

Title:
Study on the Correlation Between Thyroid Hormone and Different Stages of Type 2 Diabetic Nephropathy
文章编号:
1006-1959(2022)19-0155-04
作者:
阎 丽宋 迎
(天津市第五中心医院全科医学科,天津 300450)
Author(s):
YAN LiSONG Ying
(Department of General Medicine,Tianjin Fifth Central Hospital,Tianjin 300450,China)
关键词:
2型糖尿病肾病终末期肾衰竭甲状腺激素肾小球滤过率尿蛋白
Keywords:
Type 2 diabetic nephropathyEnd-stage renal failureThyroid hormoneGlomerular filtration rateUrine protein
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2022.19.045
文献标志码:
A
摘要:
2型糖尿病肾病是导致终末期肾衰竭的主要原因,及时评估其病情进展,同时给予积极干预,是延迟并控制终末期肾病的重要方式。甲状腺激素作为内分泌领域常见指标,现已有研究证实,该指标与2型糖尿病肾病的发生发展存在密切相关。其中,糖尿病肾病进展是引起甲状腺激素变化的重要原因,而甲状腺激素异常是导致糖尿病肾病进展的独立危险因素。本文结合2型糖尿病肾病的分期标准,针对甲状腺激素与不同阶段2型糖尿病肾病的相关性作一综述,以期为临床诊治该病提供参考。
Abstract:
Type 2 diabetic nephropathy is the main cause of end-stage renal failure. Timely assessment of its progression and active intervention are important ways to delay and control end-stage renal disease. As a common index in the field of endocrine, thyroid hormone has been proved to be closely related to the occurrence and development of type 2 diabetic nephropathy. Among them, the progress of diabetic nephropathy is an important cause of thyroid hormone changes, and thyroid hormone abnormalities are independent risk factors leading to the progress of diabetic nephropathy. Based on the staging criteria of type 2 diabetic nephropathy, this paper reviews the correlation between thyroid hormone and type 2 diabetic nephropathy in different stages, in order to provide reference for clinical diagnosis and treatment of the disease.

参考文献/References:

[1]于园园,薛淇丹,王爽,等.2型糖尿病患者甲状腺激素及抗体水平变化研究[J].中国全科医学,2021,24(3):316-321.[2]李淑雨,沈琳辉.2型糖尿病患者参考范围甲状腺激素与糖尿病肾病的相关性分析[J].内科理论与实践,2020,15(1):38-44.[3]Fei X,Xing M,Wo M,et al.Thyroid stimulating hormone and free triiodothyronine are valuable predictors for diabetic nephropathy in patient with type 2 diabetes mellitus[J].Annals of Translational Medicine,2018,6(15):305.[4]谭志敏,张燕,滕雅娟,等.糖尿病肾病患者血清甲状腺激素水平变化及其与亚临床甲状腺功能减退的相关性[J].现代检验医学杂志,2018,33(6):95-98.[5]中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏疾病防治临床指南[J].中华糖尿病杂志,2019,11(1):15-28.[6]中华医学会糖尿病学分会微血管并发症学组.糖尿病肾病防治专家共识(2014年版)[J].中华糖尿病杂志,2014,6(11):792-801.[7]郝志玲.不同分期糖尿病肾病患者蛋白尿甲状腺激素C-反应蛋白的相关性分析[J].中国药物与临床,2013,13(1):98-100.[8]吴小梅,何爱琴,鲁一兵.糖尿病肾病患者甲状腺激素水平变化及其与肾功能的关系[J].山东医药,2015(37):37-38,39.[9]周强,干正琦,方立曙,等.糖尿病肾病不同分期的甲状腺功能分析[J].浙江实用医学,2016,21(2):103-105.[10]张新,王世蓉,王刚,等.不同糖化血红蛋白水平的 2 型糖尿病患者甲状腺激素变化[J].中国医师进修杂志,2013,36(31):56-58.[11]Han Q,Zhang J,Wang Y,et al.Thyroid hormones and diabetic nephropathy: An essential relationship to recognize[J].Nephrology,2019,24(2):254-257.[12]许婧,韩洁,毕长华,等.2型糖尿病早期肾病患者尿白蛋白/肌酐比值与甲状腺自身抗体及功能的相关性研究[J].现代中西医结合杂志,2017,26(25):2805-2807.[13]孙佳,蔡筱.不同分期的糖尿病肾病患者甲状腺功能的变化及其与亚临床甲状腺功能减退的相关性[J].中国地方病防治,2020,35(4):476-479.[14]Herman-Edelstein M,Doi SQ.Pathophysiology of Diabetic Nephropathy[J].Springer International Publishing,2015:151-162.[15]王永见,戴献毅.不同阶段糖尿病肾病患者甲状腺功能变化情况分析[J].中国药物与临床,2019,19(9):1544-1546.[16]安欣,刘鲁豫,王成凯.2型糖尿病患者尿微量白蛋白肌酐比值与非酒精性脂肪性肝病相关性分析[J].陕西医学杂志,2021,50(11):1416-1419.[17]俞冰鸿.甲状腺激素与糖尿病肾脏病的相关性[D].天津: 天津医科大学,2019.[18]杜君.2型糖尿病肾病患者血清甲状腺激素水平变化及危险因素分析[J].临床合理用药杂志,2019,12(14):125-126.[19]郭丽芳,孟皓波,高爱华,等.不同分期的糖尿病肾病病人炎性因子及氧化应激指标的变化及意义研究[J].内蒙古医科大学学报,2019,41(4):370-373.[20]Mansournia N,Riyahi S,Tofangchiha S,et al.Subclinical hypothyroidism and diabetic nephropathy in Iranian patients with type 2 diabetes[J].Journal of Endocrinological Investigation,2017,40(3):289-295.[21]雷永富,李敏.住院2型糖尿病患者甲状腺激素与慢性肾脏病检出率的关系[J].临床内科杂志,2019,36(12):819-822.[22]陈晓蕾,贾农,柯亭羽,等.2型糖尿病合并亚临床甲状腺功能减低与肾脏损害相关分析[J].中国实用内科杂志,2018,38(1):65-68.[23]韦小庆,汪宏,钱光荣,等.2型糖尿病肾病患者血清甲状腺激素水平及与肾损害的相关性[J].西部医学,2019,31(5):774-777,781.[24]李京晶.对糖尿病肾病合并甲状腺功能减退症患者使用小剂量的左甲状腺素进行治疗的效果[J].当代医药论丛,2019,17(14):131-132.[25]随华,耿秀琴,周艳红,等.左旋甲状腺素对甲状腺功能减退患者肾小球滤过率的影响[J].广东医学,2015,36(6):916-918.[26]Nand L,Kumar R,Kumar K.Study of lipid profile in diabetic and non-diabetic chronic kidney disease patients on haemodialysis: a prospective comparative study from a sub Himalayan region in North India[J].International Journal of Advances in Medicine,2020,7(11):1652.[27]吴伯艳,陈建安,何永明,等.亚临床甲状腺功能减退症患者血脂和肾功能的变化[J].广东医科大学学报,2021,39(3):311-313.[28]洪燕青,邸阜生.TSH、血脂水平及肾功能、甲状腺功能与2型糖尿病患者肾损伤的相关性[J].贵州医科大学学报,2021,46(3):362-366.[29]王艳,李慧华,沈丽莎,等.老年2型糖尿病患者亚临床甲状腺功能减退与糖尿病肾病的关系[J].中华老年医学杂志,2017,36(12):1301-1303.[30]丘红梅,李薇,姚纪瑜,等.左甲状腺素对2型糖尿病早期肾病合并亚临床甲减患者肾脏损害的影响[J].实用糖尿病杂志,2017,13(5):46-47.[31]陈立,韩海滨,李佳,等.还原型谷胱甘肽对2型糖尿病早期肾病患者血浆Hcy、尿清蛋白排泄率、甲状腺功能及炎症因子的影响[J].中国中西医结合肾病杂志,2016,17(4):349-351.[32]Hyoungnae K,Yun-Ui B,Seok JJ,et al.The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy[J].Journal of Translational Medicine,2019,17(1):236.[33]孟祥凤,刘海霞,王学慧,等.2型糖尿病患者高促甲状腺激素水平与胰岛素抵抗、氧化应激的关系[J].中国现代医学杂志,2015,25(8):39-42.[34]Bellastella G,Maiorino MI,Scappaticcio L,et al. TSH oscillations in young patients with type 1 diabetes may be due to glycemic vari-ability[J].J Endocrinol Invest,2018,41(4):389-393.[35]Yi L,Sun Z.Thyroid hormone ameliorates diabetic nephropathy in a mouse model of type II diabetes[J].Journal of Endocrinology,2011,209(2):185-191.[36]陈玲,周翔海,纪立农.2型糖尿病患者微量白蛋白尿与甲状腺功能的相关性研究[J].中国糖尿病杂志,2018,26(12):1009-1012.[37]符沙沙,陈宗存,陈金逸,等.糖尿病肾病合并重度亚临床甲减患者UPCR、血清Hcy水平变化及左甲状腺素对其的影响[J].山东医药,2018,58(21):48-50.[38]袁媛,赵建国,李彬,等.甲状腺功能亢进患者甲状腺激素水平与脂糖代谢及血尿酸的相关性研究[J].国际检验医学杂志,2019,40(2):169-172.

相似文献/References:

[1]朱津津.Hcy、BNP检测在2型糖尿病肾病早期诊断中的价值分析[J].医学信息,2018,31(03):163.[doi:10.3969/j.issn.1006-1959.2018.03.060]
 ZHU Jin-jin.The Value of Hcy and BNP in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2018,31(19):163.[doi:10.3969/j.issn.1006-1959.2018.03.060]
[2]黄秉文.中美两种2型糖尿病肾病诊断标准中疾病进展及预后因素对比[J].医学信息,2018,31(22):68.[doi:10.3969/j.issn.1006-1959.2018.22.019]
 HUANG Bing-wen.Comparison of Disease Progression and Prognostic Factors in Two Diagnostic Criteria for Type 2 Diabetic Nephropathy in China and the United States[J].Journal of Medical Information,2018,31(19):68.[doi:10.3969/j.issn.1006-1959.2018.22.019]
[3]赵海莲.血尿酸水平与2型糖尿病肾病患者肾脏损害的相关性分析[J].医学信息,2020,33(06):93.[doi:10.3969/j.issn.1006-1959.2020.06.027]
 ZHAO Hai-lian.Correlation Between Serum Uric Acid Level and Renal Damage in Patients with Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2020,33(19):93.[doi:10.3969/j.issn.1006-1959.2020.06.027]
[4]段宗宝,肖三法,罗惠群.环磷酰胺联合氢氯噻嗪治疗2型糖尿病肾病的临床研究[J].医学信息,2021,34(23):159.[doi:10.3969/j.issn.1006-1959.2021.23.048]
 DUAN Zong-bao,XIAO San-fa,LUO Hui-qun.Clinical Study of Cyclophosphamide Combined with Hydrochlorothiazide in the Treatment of Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2021,34(19):159.[doi:10.3969/j.issn.1006-1959.2021.23.048]
[5]付彩雯,吴 艳.FGF23/Klotho在2型糖尿病肾病和骨质疏松共病中的研究现状[J].医学信息,2024,37(03):176.[doi:10.3969/j.issn.1006-1959.2024.03.037]
 FU Cai-wen,WU Yan.Research Status of FGF23/Klotho in the co-morbidities of Type 2 Diabetic Nephropathy and Osteoporosis[J].Journal of Medical Information,2024,37(19):176.[doi:10.3969/j.issn.1006-1959.2024.03.037]

更新日期/Last Update: 1900-01-01